BALLERUP, Denmark--(BUSINESS WIRE )--LEO Pharma A/S, a global leader in medical dermatology, will present new data and insights in moderate-to-severe atopic dermatitis and chronic hand eczema at the upcoming 31st European Academy of Dermatology and Venereology (EADV) Congress, September 7 – 10, 2022 in Milan.
Data presentations will share findings into Adtralza® (tralokinumab) for the treatment of moderate-to-severe atopic dermatitis in adults and adolescents (aged 12-17) and delgocitinib cream, an investigational topical pan-Janus kinase (JAK)-inhibitor for the potential treatment of adult patients with moderate-to-severe chronic hand eczema (CHE). Adtralza is not approved for use in adolescents aged 12 to 17 years.
Additionally, LEO Pharma will present two symposia pertaining to atopic dermatitis and chronic hand eczema.
“We look forward to sharing our latest findings and amplifying expert perspectives in moderate-to-severe atopic dermatitis and chronic hand eczema,” said Jörg Möller, Executive Vice President, Global Research and Development, LEO Pharma A/S. “We remain committed to advancing the standard of care for eczema patients and their families.”
The company’s full roster of accepted presentations and symposia at the 31st EADV Congress includes :
About atopic dermatitis Atopic dermatitis is a chronic, inflammatory skin disease characterized by intense itch and eczematous lesions.8 Atopic dermatitis is the result of skin barrier dysfunction and immune dysregulation, leading to chronic inflammation.9 Type 2 cytokines, including IL-13, play an important role in atopic dermatitis pathophysiology.10
About chronic hand eczema CHE is defined as hand eczema (HE) that lasts for more than three months or relapses twice or more within a year.11,12 HE is the most common skin disorder of the hands13 that affects an estimated 1 – 5% of the general population14 with a one-year prevalence rate of approximately 9%.15 It is an inflammatory, non-infectious skin disorder of the hands and wrists11,16 and can cause itching, blisters, swelling and pain so severe that it can impair the ability to work.11,13,17 In a substantial number of patients, HE can develop into a chronic condition.13
About Adtralza® (tralokinumab) Adtralza® (tralokinumab) is a high-affinity human monoclonal antibody developed to bind to and inhibit the interleukin (IL)-13 cytokine6, which plays a role in the immune and inflammatory processes underlying atopic dermatitis signs and symptoms.7,10 Adtralza specifically binds to the IL-13 cytokine, thereby inhibiting interaction with the IL-13 receptor α1 and α2 subunits (IL-13Rα1 and IL-13Rα2).6,10
Adtralza is approved for the treatment of adults with moderate-to-severe AD in the EU, Great Britain, Canada, the United Arab Emirates, and Switzerland.7 It also is approved in the U.S. under the tradename AdbryTM (tralokinumab-ldrm).
About delgocitinib Delgocitinib is an investigational topical pan-Janus kinase (JAK)-inhibitor that inhibits activation of the JAK-STAT pathway, which plays a key role in the immune system in driving the pathophysiology of chronic inflammatory skin diseases.18,19 LEO Pharma is currently developing delgocitinib in a cream formulation for the treatment of moderate-to-severe chronic hand eczema (CHE) in adult patients. The cream formulation of delgocitinib is an investigational therapy under clinical development and has not been approved by any regulatory authority.
In 2014, LEO Pharma A/S and Japan Tobacco Inc. (JT) entered into a license agreement in which LEO Pharma gained exclusive rights to develop and commercialize delgocitinib for topical use in dermatological indications worldwide, excluding Japan, where JT retains rights.
About LEO Pharma LEO Pharma is a global company dedicated to advancing the standard of care for the benefit of people with skin conditions, their families and society. Founded in 1908 and majority owned by the LEO Foundation, LEO Pharma has devoted decades of research and development to advance the science of dermatology, and today, the company offers a wide range of therapies for all disease severities. LEO Pharma is headquartered in Denmark with a global team of 5,800 people, serving millions of patients across the world. In 2021, the company generated net sales of DKK 9,957 million.
David Patti LEO Pharma, Global Product Communications 973.796.7706 DAPAI@leo-pharma.com
Jes Broe Frederiksen LEO Pharma, Global Communications Manager +45 53 60 59 48 JEBFE@leo-pharma.com
LEO Pharma to present new data in moderate-to-severe atopic dermatitis and chronic hand eczema at the 31st EADV Congress
David Patti LEO Pharma, Global Product Communications 973.796.7706 DAPAI@leo-pharma.com
Jes Broe Frederiksen LEO Pharma, Global Communications Manager +45 53 60 59 48 JEBFE@leo-pharma.com